E-Mail
PHILADELPHIA - A machine learning-based tool was able to predict the risk of malignancy among patients presenting with multiple pulmonary nodules and outperformed human experts, previously validated mathematical models, and a previously established artificial intelligence tool, according to results published in
Clinical Cancer Research, a journal of the American Association for Cancer Research.
Tools currently available can predict malignancy in patients with single nodules; predictive tools for patients presenting with multiple nodules are limited. With the adoption of widespread use of thoracic computed tomography (CT) for lung cancer screening, the detection of multiple pulmonary nodules has become increasingly common, said study author Kezhong Chen, MD, vice professor in the Department of Thoracic Surgery at Peking University People s Hospital in China. Among patients presenting with a pulmonary nodule on a CT scan in a previous lung cancer screening trial, rough
AACR Initiatives Bolster Diversity, Take Aim at Disparities - American Association for Cancer Research (AACR)
aacr.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aacr.org Daily Mail and Mail on Sunday newspapers.
COVID: Cancer patients frustrated as they continue to wait for vaccine
usatoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from usatoday.com Daily Mail and Mail on Sunday newspapers.
AnchorDx Completes USD 40 Million Series C Financing to Advance Cancer Screening and Early Detection Programs
News provided by
Share this article
Share this article
GUANGZHOU, China, Feb. 22, 2021 /PRNewswire/ AnchorDx Medical Co., Ltd. ( AnchorDx ) announced the completion of a USD 40 million Series C financing. This round of financing was jointly led by OrbiMed, a world-renowned biomedicine and healthcare venture capital fund, and WuXi Huiying Investment, an investment fund focusing on the health and wellness industry. To date, AnchorDx has successfully attracted well-known investors including the top biopharmaceutical and medical diagnosis companies Wuxi AppTec and KingMed Diagnostics, as well as leading investment funds such as Northern Light Venture Capital, 6 Dimensions Capital, Serica Jianxin Venture Capital, Arch Venture Partners, Marathon Venture Partners, OrbiMed, and WuXi Huiying Investment.
Preventing Cancer: The Seven Essentials
aacr.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aacr.org Daily Mail and Mail on Sunday newspapers.